(HealthDay News) — Chronic proton pump inhibitor (PPI) exposure is associated with mild hyperparathyroidism in elderly adults, according to a study published in the Journal of the American Geriatrics Society.
Andrew M. Hinson, MD, from the University of Arkansas for Medical Sciences in Little Rock, and colleagues examined the effect of PPIs with and without concurrent bisphosphonates on parathyroid hormone (PTH), vitamin D, and calcium in a retrospective chart review of individuals aged 60 years and older. Data were included for 80 individuals meeting inclusion criteria.
The researchers found that, compared with no PPI exposure, chronic PPI exposure correlated with significantly higher PTH (65.5 pg/mL vs 30.3 pg/mL; P<.001) and lower calcium (9.1 mg/dL vs 9.4 mg/dL; P=.02). Compared with bisphosphonate therapy alone, chronic PPI exposure with concurrent bisphosphonate therapy was associated with significantly higher PTH (65.2 pg/mL vs 43.4 pg/mL; P=.05) and lower calcium (9.2 mg/dL vs 9.6 mg/dL; P=.04).
Continue Reading
“Based on the present study, chronic PPI exposure in elderly adults is associated with mild hyperparathyroidism regardless of concurrent oral [bisphosphonate] administration,” the researchers wrote.
Enjoying our content?
Thanks for visiting Endocrinology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Endocrinology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.